公开(公告)号：US20220119391A1

公开(公告)日：2022-04-21

申请号：US17299659

申请日：2019-12-04

Applicant: SCOHIA PHARMA, INC.

Inventor： Shigemitsu MATSUMOTO ,  Ryoma HARA ,  Naoyoshi NOGUCHI ,  Hideto FUKUSHI ,  Ayumu NIIDA ,  Satoshi SASAKI ,  Minoru IKOMA ,  Toshitake KOBAYASHI ,  Tsuyoshi MAEKAWA

IPC: C07D471/18 ,  C07D498/22 ,  C07D491/22 ,  C07D498/16

Abstract: Compounds represented by the following formula (I): wherein each symbol in the formula is as described herein, or a salt thereof, and compositions comprising the same, and methods of using the same as an NRF2 activator and/or a preventive or therapeutic agent for diseases associated with oxidative stress, in particular, hepatic disease (for example, non-alcoholic steatohepatitis (NASH)), cardiovascular disease (for example, heart failure or pulmonary arterial hypertension), lung disease (for example, chronic obstructive pulmonary disease (COPD)), kidney disease (for example, chronic kidney disease (CKD) or acute kidney injury (AKI)), central nervous system disease (for example, Parkinson's disease), mitochondrial disease (for example, Friedreich motor ataxia, mitochondrial myopathy), inflammatory disease (for example, multiple sclerosis (MS), inflammatory bowel disease (IBD)), sickle cell disease, cancer, or the like.

公开(公告)号：US20200377509A1

公开(公告)日：2020-12-03

申请号：US16497141

申请日：2018-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  SCOHIA PHARMA, INC

Inventor： Seiji MIWATASHI ,  Yasufumi MIYAMOTO ,  Koji WATANABE ,  Yayoi NAKAYAMA ,  Yuko HITOMI ,  Jumpei AIDA ,  Nobuyuki TAKAKURA ,  Hideki FURUKAWA ,  Naoyoshi NOGUCHI ,  Yasuhiro HIRATA ,  Shizuo KASAl ,  Toshitake KOBAYASHI ,  Tsuyoshi MAEKAWA ,  Satoshi SASAKI ,  Shigemitsu MATSUMOTO

IPC: C07D491/052 ,  C07D401/12 ,  C07D401/14 ,  C07D211/22

Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.